Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00870220 · ClinicalTrials.gov registry record · Phase 1
Initiating Transdermal Estradiol Therapy in Turner's Syndrome
A Phase 1 study, sponsored by University of Chicago.
- Terminated
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT00870220 is a Phase 1 study that was terminated before completion, run by University of Chicago. The registered enrollment target is 1 participants.
The verdict
NCT00870220, a Phase 1 study, was terminated before completion, sponsored by University of Chicago.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
This is a multicenter, randomized, controlled, semi-blinded study to compare two low doses of estradiol administered by recently available transdermal patches for the initiation of puberty in Turner syndrome girls 11.5-13.0 years old in conjunction with growth hormone (GH) therapy. The specific hypotheses to be tested are: when combined with growth hormone (GH) treatment, low dose transdermal estradiol (LTE2) replacement will be more effective in stimulating feminization, height velocity, and bone mineral density without compromising growth potential than very low dose transdermal estradiol (VLTE2), which will in turn be superior to GH alone in effects on feminization, height velocity, and bone mineral density.
Interventions
- DRUG Norditropin, Menostar 14mcg patch, Vivelle dot 25mcg patch
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2009-04 |
| Est. Completion | 2011-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00870220
The ClinicalTrials.gov registry entry for NCT00870220 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Norditropin, Menostar 14mcg patch, Vivelle dot 25mcg patch is the first listed.
NCT00870220 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00870220 about?
NCT00870220 is a clinical study titled "Initiating Transdermal Estradiol Therapy in Turner's Syndrome". This is a multicenter, randomized, controlled, semi-blinded study to compare two low doses of estradiol administered by recently available transdermal patches for the initiation of puberty in Turner syndrome girls 11.5-13.0 years old in conjunction with growth hormone (GH) therapy. The specific hyp...
What is the current status of trial NCT00870220?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2009-04. Estimated completion is 2011-03.
What interventions are being tested in trial NCT00870220?
The interventions under investigation include: Norditropin, Menostar 14mcg patch, Vivelle dot 25mcg patch (DRUG).
Who is sponsoring clinical trial NCT00870220?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.